INVO FERTILITY INC (IVF)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$0.98+0.16%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · IVF
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -88.5% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 80.6% |
Growth built into the price is above our model estimate.
The price assumes 169.0 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 88 industry peers · Company calendar date is not available
IVF — capital allocation — Unregistered Sales of Equity Securities The
Dated 2026-07-24
Unregistered Sales of Equity Securities The information contained above in
Why it matters: Better Adjusted EBITDA means the company is more efficient. It also shows better financial health.
Supportive ifAdjusted EBITDA gets less negative than $(1.26) million in Q2 2026.
Worry ifAdjusted EBITDA stays more negative than $(1.26) million in Q2 2026.
Why it matters: A compliance plan is important to prevent being removed from Nasdaq.
Worry ifThe company submits a plan to Nasdaq within the 60-day window.
Less concerning ifThe company fails to submit a compliance plan by the deadline.
Why it matters: New acquisitions or partnerships can boost growth and increase market presence.
Supportive ifThere is an announcement of at least one new acquisition or partnership.
Worry ifNo new acquisitions or partnerships announced in the next quarter.
Why it matters: Fixing compliance issues would help investors feel more confident and stabilize the stock.
Supportive ifINVO submits a compliance plan to Nasdaq and receives approval.
Worry ifNasdaq rejects INVO's compliance plan or issues a delisting notice.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$296 on $10,000 · ±3.0% | How much price usually moves either way. |
| Bad day | $1,577 loss on $10,000 · 15.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,838 loss on $10,000 · 98.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Growth from acquisitions can signal successful expansion. It is key for future revenue.
Supportive ifRevenue increases beyond $2.02M in Q2 2026, showing growth from acquisitions.
Worry ifRevenue falls or stays below $2.02M, showing trouble with acquisitions.
Why it matters: Better operating income means the company is controlling costs. This affects overall health.
Supportive ifOperating income loss narrows to less than $1.59M in Q2 2026.
Worry ifOperating income loss grows beyond $1.59M, showing worse cost management.
Why it matters: Growth at the Atlanta clinic shows the success of new initiatives. This could help finances.
Supportive ifAtlanta clinic revenue goes up by more than 10% each quarter.
Worry ifAtlanta clinic revenue stays the same or goes down each quarter.
Why it matters: Filing the Annual Report is crucial to regain compliance with Nasdaq. Failure to file could lead to delisting.
Worry ifThe Annual Report is filed by the deadline of June 22, 2026.
Less concerning ifThe Annual Report is late. This causes more regulatory problems.
Why it matters: This growth shows that INVO's growth and buying plans are working well.
Supportive ifQ3 revenue growth of 17% or more compared to Q3 2025.
Worry ifQ3 revenue growth falls below 10% compared to Q3 2025.
Why it matters: More cash means better financial health. This helps support growth plans.
Supportive ifCash position exceeds $4 million by Q3 2026.
Worry ifCash position falls below $3 million by Q3 2026.
Why it matters: Buying successful clinics can help grow and make more money in the long run.
Supportive ifA new purchase of a profitable fertility clinic will be announced by the end of Q3 2026.
Worry ifNo new acquisitions announced by the end of Q3 2026.